More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...

For too long, people living with rare diseases have faced uncertainty, delays, and unacceptable variation in the care they receive. The launch of this quality standard is a watershed moment. For the ...

NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...

NICE is unable to make a recommendation on canagliflozin (Invokana) for treating type 2 diabetes in children and young people 10 to 17 years. This is because the company did not provide an evidence ...

In 2025, we introduced a new collaborative Biosimilar Taskforce to address this potentially transformative area. The taskforce coordinates activity across the system , optimise biosimilar uptake and ...